Department Ritsumeikan Asia Pacific University College of International Management Position Professor
|Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin.
|Volume, Issue, Page
|Total page number
|Lead author,Corresponding author
|Author and coauthor
|Technological trends and origin of FIC drugs approved by FDA from 2011-2022 were analyzed. The analysis reveals that the target family of FIC drugs has shifted to molecules previously considered challenging as drug targets. It also reveals that the drug modalities used for new drugs have been diversified in recent years. Over half of FIC drugs were created by small and medium enterprises (SMEs), especially young companies established in the 1990s and 2000s. All SMEs with high productivity have the strong technological capability in a specific modality. Investment in modality technologies and facilitating mechanisms to translate academic modality technologies to start-ups might be important for enhancing FIC drug development.